FDA-Approved Sodium Tetradecyl Sulfate Injection is offering a safe and efficient solution for patientsgiving healthcare systems and healthcare providers, peace of mind.
FREMONT, CA: A U.S. innovator in generic drug products, Leucadia Pharmaceuticals, has launched FDA-approved Sodium Tetradecyl Sulfate (STS) generic. STS injection is a regulated sclerosing agent that is therapeutically equivalent to SOTRADECOL and is an effective option to the use of unapproved compounded products. The regulated sclerosing agent is AP rated, barcoded, and does not contain natural rubber latex and is used to operate small varicose veins of the lower legs. Patients do not have many options while seeking an affordable generic alternative to Sotradecol. This, in turn, has resulted in some of the patients to turn to compound pharmacies.
Leucadia's FDA-approved STS now offers a safer alternative while also giving healthcare providers and healthcare systems, peace of mind. According to industry analysis, several drugs that are produced by compounding pharmacies have put patient safety at risk. This has resulted in numerous tainted drug lawsuits against both hospitals and individual health care providers. According to a research led by Dr. Mitchel Goldman, past president of the (ASDS) and past president of the American Vein & Lymphatic Society, some compounding pharmacies were producing 3% sodium tetradecyl sulfate by simple dilution of 27% industrial detergent solution that is not manufactured for use in humans.
Leucadia Pharmaceuticals is a U.S. innovator in generic drug products and the commercial sales arm of Custopharm, Inc. The company aims to provide essential new generic injectable products to the acute markets and to reach conditions and communities that are under-served.